Generated by AI
Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company’s current work centers on treating difficult solid tumors, with an emphasis on pancreatic cancer and other malignancies linked to KRAS mutations. Its pipeline includes SIL204, a lead siRNA-based candidate designed to silence mutant KRAS using both local and systemic delivery approaches, as well as additional product programs under its LODER delivery platform. Silexion Therapeutics Corp. operates as an oncology-focused developer of targeted genetic therapies, combining drug design and delivery technology to address areas of unmet medical need in cancer treatment.
Website12 Abba Hillel Road
Ramat Gan, 5250606
Israel
The latest articles about SLXN.
Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its market position, and support its clinical progress with SIL204 Grand Cayman, Cayman Islands, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-dr
Tipranks Press Release.
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stock
Silexion Therapeutics has moved SIL204 into active patient treatment, beginning a multinational Phase 2/3 study that will evaluate the RNAi candidate alongside standard chemotherapy in locally advanced pancreatic cancer. Key Investor TakeawaysSilexion Therapeutics (NASDAQ:SLXN) has successfully dosed the first patient in its Phase 2/3 SIL204 trial, moving the programme into active clinical execution.
Summary of Oct 26's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Investors talking about SLXN also mention these. Each card shows that asset’s own numbers for the past 24 hours.